Transdermal delivery of a broader range of therapeutics could be possible using microdevice fabrication technology Vyteris inked a deal to access.
Manufacturing drug delivery micro-structures using milder conditions could increase the range of therapeutics that can tolerate the process. Transdermal delivery would then be viable for a wider range of drugs.
Vyteris is researching such a mild microdevice fabrication process having inked a deal with Georgia Tech Research Corporation. The deal gives Vyteris the option to exclusively license the technology.
Georgia Tech developed the technology and will collaborate with Vyteris to identify compounds it can be applied to. The deal includes thermal ablation technology which the organisations will also collaboratively develop.
Using the thermal ablation technology skin permeation can be selectively enhanced. This is achieved by selectively heating the skin for microseconds to milliseconds, creating micron-scale perforations.
Creating larger holes in the stratum corneum allows therapeutics of higher molecular weight, such as peptides and proteins, to pass through the skin and enter into the circulatory system.
Haro Hartounian, CEO of Vyteris, said the two technologies could improve the company’s existing transdermal capabilities. Vyteris markets a US Food and Drug Administration (FDA) approved active drug delivery patch and has a number of products in the pipeline.
"Georgia Tech's thermal ablation and microdevice fabrication technologies are potentially complementary to our active transdermal smart patch technology, and may allow Vyteris to deliver a much broader range of therapeutic drugs through the skin”, said Hartounian.